Thromboembolism in adult patients with acute promyelocytic leukemia: clinical characteristics, risk factors, and a predictive nomogram

成人急性早幼粒细胞白血病患者的血栓栓塞:临床特征、危险因素和预测列线图

阅读:1

Abstract

Acute promyelocytic leukemia (APL) is typically associated with bleeding, whereas thromboembolism (TE) is a less common cause of early death (ED) and frequently underestimated complication. To investigate the clinical characteristics and predictive risk factors for TE, we conducted this retrospective study. Our study included 306 patients diagnosed with APL at the Second Hospital of Shanxi Medical University between May 2012 and May 2023. Among them, 16(5.2%) patients (11 males and 5 females, with a median age of 58 years) experienced TE, including 13 cases of arterial TE (10 cerebral infarctions and three myocardial infarctions), one case of combined arterial and venous TE, and two cases of venous TE. Multivariate logistic regression analysis revealed age (OR 1.08, 95% CI 1.03-1.13, p = 0.001), smoking (3.26, 1.01-10.49, p = 0.048), alkaline phosphatase (ALP) > 125U/L (10.8, 2.26-51.46, p = 0.021), and serum creatinine (SCr) > 62µmol/L (7.09, 1.35-37.35, p = 0.003) as independent risk factors for TE in newly diagnosed APL patients. A nomogram incorporating the four aforementioned predictive factors demonstrated high accuracy and clinical applicability. With a median follow-up of 6.6 years (range: 0.6-11.8 years), the overall survival (OS) rate for all patients was 86.2%. When excluding patients who succumbed to ED, the OS rate increased to 96.2%. Importantly, there was no statistically significant difference in OS rates between non-ED patients with and without TE (p = 0.405). Our findings underscore that age, smoking, ALP, and SCr are four independent risk factors for TE in APL. Furthermore, TE primarily affects early survival but not OS rates in APL patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。